MetLife (MET) has affirmed its shareholder payout plans, with the board declaring a third quarter 2026 common stock dividend of $0.5925 per share, payable on September 8 to holders of record on August 4.

At a share price of $92.54, MetLife has seen a 30 day share price return of 4.16% and a 90 day share price return of 19.38%. The 1 year total shareholder return of 25.07% and 5 year total shareholder return of 86.76% indicate a strong longer term outcome, suggesting current dividend plans are unfolding against building momentum rather than a short lived bounce.

If this kind of steady progress appeals to you, it could be a good moment to broaden your watchlist and check out opportunities in 18 top founder-led companies

After a strong 3 month run and a fresh dividend affirmation, MetLife now sits close to its recent highs. Is it better to accept today’s price, or wait in case the stock offers a cheaper entry?

Most Popular Narrative: 3% Undervalued

MetLife is trading at $92.54 against a widely followed fair value estimate of $95.31, so the current dividend decision sits within a modest valuation gap.

Strategic expansion of asset-light, fee-generating businesses (such as employee benefits, asset management, and longevity reinsurance), combined with disciplined capital management, supports higher return on equity and more consistent, less capital-intensive earnings growth.

Want to see what is really driving that fair value? The narrative leans on measured revenue growth, firmer margins and a lower future earnings multiple than many peers.

Result: Fair Value of $95.31 (UNDERVALUED)

However, the MetLife narrative could be challenged if commercial mortgage loan credit losses rise further, or if weaker investment margins and Asia underwriting pressure persist.

Another View: MetLife Through Earnings Multiples

The earlier fair value work suggests MetLife is modestly undervalued, but the current P/E of 17.3x tells a tougher story. It sits above the US Insurance industry at 12.6x, the peer average at 13.1x, and even a fair ratio of 14.3x. This raises the question of how much optimism is already in the price.

See what the numbers say about this price in more detail in our valuation breakdown, and consider how that gap between current P/E, peers, and the fair ratio affects your own risk tolerance before making any moves. See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on MetLife so far? If this balance of risks and rewards interests you, review the data now and weigh the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond MetLife?

MetLife offers plenty to think about, but you will widen your edge by comparing it with other clear, data driven opportunities before making any portfolio moves.

• Target consistent compounding potential by reviewing companies in the 44 high quality undervalued stocks that combine attractive pricing with solid fundamentals.
• Strengthen your income stream by checking out stocks in the 8 dividend fortresses that focus on higher yields with durability in mind.
• Limit downside risk by scanning companies in the 79 resilient stocks with low risk scores that emphasise resilience and financial stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.